Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 329

1.

Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.

French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; American Academy of Neurology Therapeutics and Technology Assessment Subcommittee; American Academy of Neurology Quality Standards Subcommittee; American Epilepsy Society Therapeutics and Technology Assessment Subcommittee; American Epilepsy Society Quality Standards Subcommittee.

Epilepsia. 2004 May;45(5):410-23. Review. Erratum in: Epilepsia. 2004 Nov;45(11):1299.

2.

Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.

French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; American Academy of Neurology Therapeutics and Technology Assessment Subcommittee; American Academy of Neurology Quality Standards Subcommittee; American Epilepsy Society Quality Standards Subcommittee; American Epilepsy Society Therapeutics and Technology Assessment Subcommittee.

Epilepsia. 2004 May;45(5):401-9. Review.

3.

Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society.

Neurology. 2004 Apr 27;62(8):1261-73. Review.

PMID:
15111660
4.

Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society.

Neurology. 2004 Apr 27;62(8):1252-60. Review.

PMID:
15111659
5.

Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.

Nevitt SJ, Sudell M, Weston J, Tudur Smith C, Marson AG.

Cochrane Database Syst Rev. 2017 Jun 29;6:CD011412. doi: 10.1002/14651858.CD011412.pub2. Review.

PMID:
28661008
6.

The 'number needed to treat' with levetiracetam (LEV): comparison with the other new antiepileptic drugs (AEDs).

van Rijckevorsel K, Boon PA.

Seizure. 2002 Apr;11 Suppl A:235-6. No abstract available.

PMID:
12185762
7.

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.

Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O'Meara S, Sculpher M, Drummond M, Forbes C.

Health Technol Assess. 2005 Apr;9(15):1-157, iii-iv. Review.

8.

Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Patsalos PN, Sander JW.

Drug Saf. 1994 Jul;11(1):37-67. Review.

PMID:
7917080
9.

Novel anticonvulsant drugs.

Stefan H, Feuerstein TJ.

Pharmacol Ther. 2007 Jan;113(1):165-83. Epub 2006 Oct 9. Review.

PMID:
17030393
10.

The new antiepileptic drugs: scientific review.

LaRoche SM, Helmers SL.

JAMA. 2004 Feb 4;291(5):605-14. Review.

PMID:
14762040
11.

A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial.

Marson AG, Appleton R, Baker GA, Chadwick DW, Doughty J, Eaton B, Gamble C, Jacoby A, Shackley P, Smith DF, Tudur-Smith C, Vanoli A, Williamson PR.

Health Technol Assess. 2007 Oct;11(37):iii-iv, ix-x, 1-134.

12.

The new antiepileptic drugs: a systematic review of their efficacy and tolerability.

Marson AG, Kadir ZA, Hutton JL, Chadwick DW.

Epilepsia. 1997 Aug;38(8):859-80.

13.

Antiepileptic drug therapy for adults: when to initiate and how to choose.

Sirven JI.

Mayo Clin Proc. 2002 Dec;77(12):1367-75. Review.

PMID:
12479527
14.

Epilepsy in children: the evidence for new antiepileptic drugs.

Verdru P.

Acta Neurol Scand Suppl. 2005;181:17-20.

PMID:
16238703
15.

Antiepileptic drugs in development: prospects for the near future.

Leppik IE.

Epilepsia. 1994;35 Suppl 4:S29-40. Review.

PMID:
8174517
17.

[Efficacy and tolerability of topiramate, lamotrigine, and levetiracetam in children with refractory epilepsy].

Kato T, Nakata M, Ide M, Saito K, Yoshida T, Awaya T, Heike T.

No To Hattatsu. 2015 Sep;47(5):354-9. Japanese.

PMID:
26502652
18.
19.

[Clinical application of newer anti-epileptic drugs].

Terada K, Inoue Y.

Rinsho Shinkeigaku. 2012;52(11):1088-90. Japanese.

PMID:
23196525
20.

Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy.

Lhatoo SD, Wong IC, Polizzi G, Sander JW.

Epilepsia. 2000 Dec;41(12):1592-6.

Supplemental Content

Support Center